Corautus Genetics (CAQ) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Corautus Genetics (CAQ)

An SI Board Since February 2003

Posts	SubjectMarks	Bans	Symbol
52	5	0	VEGF

Emcee: Paul Lee	Type: Unmoderated

Introduction Market Data Compact

Corautus Genetics was created to capitalize on the complementary strengths of GenStar and VGI to accelerate the development of a later stage genetic therapy for cardiovascular disease. The focus of the company's efforts will be the clinical development of gene therapy products using Vascular Endothelial Growth Factor 2 (VEGF-2), a vascular growth factor gene.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
52	Back to 0.18 after a spike with purchase of patent rights to few new technologie	mlkr	-	1/6/2009
51	Paul Lee; VEGF's name change to VIAP ; can you change board name? There is a	mlkr	-	10/12/2007
50	looking good; step by step to being a formidable company again.. first clearanc	mlkr	-	10/11/2007
49	VIA Pharmaceuticals Announces Grant of New Patent Rights - Phosphodiesterase Inh	Paul Lee	-	8/6/2007
48	well, i hope, rather, i pray	Paul Lee	-	5/22/2007
47	paul How is merging going to work? tia	mlkr	-	5/21/2007
46	Corautus Genetics and VIA Pharmaceuticals Announce Merger Agreement Thursday Feb	Paul Lee	-	2/8/2007
45	paul Lee why 2 boards? one for IHUB other Silicon Valley Investor? do u follow	mlkr	-	12/28/2006
44	nothing to say, waiting to hear what they plan to do with their cash. Could be	Paul Lee	-	12/28/2006
43	HOW COME NO LIFE HERE?	mlkr	-	12/27/2006
42	Corautus Genetics Announces Partial Lifting of FDA Clinical Hold and Update on G	Paul Lee	-	7/13/2006
41	Corautus Genetics Announces Filing of Response to FDA Clinical Hold Wednesday Ma	Paul Lee	-	5/31/2006
40	Corautus Genetics Announces Update on GENASIS Trial Thursday February 23, 8:00 a	Paul Lee	-	2/23/2006
39	Corautus Genetics Announces Collaboration for Phase I Trial for the Treatment of	Paul Lee	-	1/11/2006
38	Corautus Genetics Reports Third Quarter Results Thursday November 10, 8:00 am ET	Paul Lee	-	11/10/2005
37	Corautus Genetics Receives FDA Fast Track Designation for VEGF-2 Thursday Novemb	Paul Lee	-	11/3/2005
36	Shands work may help heart treatment Blood vessel growth -- if approved -- coul	Paul Lee	-	9/16/2005
35	Corautus hopes heart therapy passes big test Erin Moriarty Staff writer An Atla	Paul Lee	-	8/22/2005
34	Corautus Genetics Announces Collaboration and Licensing Agreement for Treatment	Paul Lee	-	8/10/2005
33	Corautus Genetics Inc. Announces Boston Scientific Transactions and Separate Pri	Paul Lee	-	6/28/2005
32	Corautus Genetics Inc. Enters Into Long Term Manufacturing Agreement With Boehri	Paul Lee	-	5/16/2005
31	Corautus Genetics Inc. Announces Publication of Positive Gene Therapy Trial Resu	Paul Lee	-	3/8/2005
30	Rush Physicians Using Gene Therapy for Heart Patients with Moderate to Severe C	Paul Lee	-	1/30/2005
29	Wednesday, January 26 Cardiac Gene Therapy Trial -- The idea of a new heart s	Paul Lee	-	1/30/2005
28	News article 1/24/05 This patient taking heart An experimental therapy shows p	Paul Lee	-	1/30/2005

Go to reply# or date (mm/dd/yy):